Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study

Tankova, Tsvetalina; Еленкова, Атанаска; Robeva, Ralitsa; Dimova, Rumyana; Borissovа, Anna-Maria; Olszewski, Adrian; Lachev, Vasil I.; Petkova, Reneta

doi:10.1007/s13300-019-00748-2

Cited by 1 publication

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a novel study analyzing a database of diabetes centers across Bulgaria, DLCNS was calculated and a total of 450 diabetic patients were identified as FH patients. A noticeable finding of the study is that only one patient (<1%) achieved the LDL-C target recommended for very high-risk patients, but the glycated hemoglobin target level was only reached in 30% of the patients; however, diabetes might had not been newly diagnosed [ 96 ].…”

Section: Endocrine Disordersmentioning

confidence: 99%

Clinical Aspects of Genetic and Non-Genetic Cardiovascular Risk Factors in Familial Hypercholesterolemia

Berta

Zsíros

Bodor

et al. 2022

Genes

View full text Add to dashboard Cite

Familial hypercholesterolemia (FH) is the most common monogenic metabolic disorder characterized by considerably elevated low-density lipoprotein cholesterol (LDL-C) levels leading to enhanced atherogenesis, early cardiovascular disease (CVD), and premature death. However, the wide phenotypic heterogeneity in FH makes the cardiovascular risk prediction challenging in clinical practice to determine optimal therapeutic strategy. Beyond the lifetime LDL-C vascular accumulation, other genetic and non-genetic risk factors might exacerbate CVD development. Besides the most frequent variants of three genes (LDL-R, APOB, and PCSK9) in some proband variants of other genes implicated in lipid metabolism and atherogenesis are responsible for FH phenotype. Furthermore, non-genetic factors, including traditional cardiovascular risk factors, metabolic and endocrine disorders might also worsen risk profile. Although some were extensively studied previously, others, such as common endocrine disorders including thyroid disorders or polycystic ovary syndrome are not widely evaluated in FH. In this review, we summarize the most important genetic and non-genetic factors that might affect the risk prediction and therapeutic strategy in FH through the eyes of clinicians focusing on disorders that might not be in the center of FH research. The review highlights the complexity of FH care and the need of an interdisciplinary attitude to find the best therapeutic approach in FH patients.

show abstract

Section: Endocrine Disordersmentioning

confidence: 99%